Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 13 04:00PM ET
0.7090
Dollar change
+0.0344
Percentage change
5.10
%
Index- P/E- EPS (ttm)-1.81 Insider Own2.00% Shs Outstand14.91M Perf Week28.84%
Market Cap10.57M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float14.62M Perf Month321.02%
Income-7.93M PEG- EPS next Q-0.17 Inst Own22.26% Short Float43.47% Perf Quarter80.32%
Sales4.42M P/S2.39 EPS this Y76.33% Inst Trans- Short Ratio0.23 Perf Half Y15.83%
Book/sh0.22 P/B3.20 EPS next Y39.64% ROA-125.77% Short Interest6.35M Perf Year-14.94%
Cash/sh0.28 P/C2.55 EPS next 5Y- ROE-196.55% 52W Range0.14 - 2.06 Perf YTD-33.11%
Dividend Est.- P/FCF- EPS past 5Y- ROI-438.48% 52W High-65.58% Beta0.68
Dividend TTM- Quick Ratio1.88 Sales past 5Y-10.06% Gross Margin- 52W Low402.12% ATR (14)0.13
Dividend Ex-Date- Current Ratio3.24 EPS Y/Y TTM91.82% Oper. Margin-142.70% RSI (14)64.94 Volatility21.74% 28.26%
Employees9 Debt/Eq0.07 Sales Y/Y TTM40.41% Profit Margin-179.29% Recom1.00 Target Price8.60
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q108.03% Payout- Rel Volume0.64 Prev Close0.67
Sales Surprise-33.33% EPS Surprise43.59% Sales Q/Q685.26% EarningsAug 14 BMO Avg Volume27.20M Price0.71
SMA2042.72% SMA5095.77% SMA20022.89% Trades Volume17,505,745 Change5.10%
Nov-12-24 04:15PM
Nov-07-24 08:00AM
Oct-08-24 08:00AM
Oct-02-24 08:00AM
Sep-27-24 04:30PM
08:00AM Loading…
Sep-24-24 08:00AM
Sep-19-24 07:00AM
Sep-13-24 08:00AM
Aug-29-24 08:00AM
08:00AM
Aug-27-24 02:30PM
08:00AM
Aug-23-24 08:00AM
Aug-14-24 04:15PM
Aug-08-24 08:25AM
08:00AM Loading…
Jul-23-24 08:00AM
Jul-09-24 08:00AM
Jun-27-24 08:00AM
Jun-25-24 08:00AM
Jun-24-24 10:52AM
Jun-06-24 08:00AM
Jun-03-24 08:00AM
May-28-24 08:00AM
May-20-24 08:00AM
May-13-24 08:00AM
Apr-25-24 08:00AM
Apr-19-24 08:00AM
Apr-09-24 08:00AM
Mar-18-24 10:53AM
Mar-15-24 08:00AM
08:00AM Loading…
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-15-24 08:00AM
Feb-13-24 08:00AM
Feb-06-24 08:00AM
Jan-31-24 08:00AM
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-08-24 08:15AM
Dec-19-23 04:15PM
Dec-14-23 08:15AM
Dec-11-23 09:00AM
Nov-29-23 08:05AM
Nov-28-23 08:15AM
Nov-16-23 08:15AM
Nov-09-23 04:30PM
Oct-24-23 08:15AM
Oct-18-23 08:15AM
Oct-13-23 08:15AM
Oct-11-23 08:15AM
Oct-03-23 08:15AM
Sep-26-23 08:15AM
Sep-19-23 08:15AM
Sep-14-23 08:15AM
Sep-07-23 08:15AM
Sep-05-23 08:15AM
Aug-14-23 08:15AM
Aug-11-23 08:00AM
Aug-08-23 08:15AM
07:05AM
Jul-26-23 08:05AM
Jun-27-23 08:05AM
Jun-15-23 01:34PM
Jun-13-23 04:15PM
Jun-07-23 09:55AM
Jun-06-23 08:05AM
May-16-23 07:25AM
May-15-23 04:30PM
May-12-23 04:40PM
May-10-23 08:00AM
May-09-23 01:31PM
08:00AM
07:45AM
Apr-21-23 03:59PM
Apr-19-23 09:25AM
Apr-11-23 08:10AM
Apr-03-23 08:06AM
08:00AM
Mar-30-23 05:37PM
Mar-22-23 08:05AM
07:32AM
Mar-09-23 03:42PM
Mar-06-23 08:05AM
Feb-28-23 08:05AM
Feb-23-23 08:05AM
Feb-15-23 04:10PM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
06:10AM
Feb-03-23 08:00AM
Feb-01-23 08:05AM
Jan-25-23 08:05AM
Jan-23-23 08:05AM
08:00AM
Jan-11-23 08:00AM
Jan-04-23 08:05AM
Dec-19-22 08:05AM
Dec-14-22 08:00AM
Dec-08-22 06:20AM
Dec-07-22 08:00AM
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.